Genomically Edited iPSC Effector Cells for Multi-Antigen Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adoptive cell therapies using patient- and donor-sourced cells face challenges in achieving consistent manufacturing, efficacy, persistence, and uniformity of lymphocytes such as T cells and NK cells, with issues including response rate, cell exhaustion, tumor escape, off-target toxicity, and efficacy against solid tumors.
Innovation Solution
The development of genomically edited iPSC-derived non-pluripotent cells with targeted genetic modifications, such as CD38 knockout and expression of exogenous proteins like high affinity CD16 and IL15/IL15 receptor fusion, enables stable integration of chimeric antigen receptors, enhancing therapeutic properties like engraftment, trafficking, and cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple different CARs are expressed in separate T cells to target multiple tumor antigens, then the ability to recognize and kill diverse tumor cells is improved, but the complexity of cell production and the risk of off-target effects increase
Solution Approach 1:
The patent combines multiple different CARs into a single T cell through polycistronic mRNA expression. The T cell receives a single mRNA construct that encodes multiple CARs with different specificities, allowing one cell to perform multiple targeting functions simultaneously. This merging approach simplifies the production process by eliminating the need to produce and mix multiple separate CAR-T cell products.
Solution Approach 2:
The engineered T cell is designed to be multi-functional by expressing multiple CARs with different antigen specificities within the same cell. This universal T cell can recognize and respond to multiple different tumor antigens, making it adaptable to various tumor types and reducing the need for multiple specialized cell products.
2Adaptability or versatility
If multiple different CARs are expressed in separate T cells to target multiple tumor antigens, then the ability to recognize and kill diverse tumor cells is improved, but the risk of off-target effects and toxicity increases
Solution Approach 1:
The patent incorporates safety switch mechanisms that allow for controlled deactivation of the CAR-T cells. The system includes suicide genes and regulatory elements that enable feedback control - if off-target effects occur or persistence becomes problematic, the cells can be selectively eliminated. This feedback mechanism reduces the risk of harmful long-term effects while maintaining the multi-targeting capability.
Solution Approach 2:
The patent uses inducible expression systems where the expression of multiple CARs can be controlled and adjusted. By changing the expression parameters through external inducers, the system can modulate the activity level of different CARs to minimize off-target effects while maintaining effectiveness against tumor antigens. This allows dynamic adjustment of the immune response intensity.
3Reliability
If traditional separate CAR-T cell products are used for each tumor antigen, then the specificity to each antigen is maintained, but the number of infusions and treatment complexity increases
Solution Approach 1:
The patent merges multiple CAR-T cell products into a single polycistronic mRNA-based T cell product. Instead of producing separate T cell populations for each antigen and requiring multiple infusions, the invention creates one unified cell product that expresses multiple CARs simultaneously, reducing the number of administrations needed while maintaining antigen-specific recognition.
Solution Approach 2:
The patent performs preliminary action by pre-engineering T cells to express multiple CARs through polycistronic mRNA before infusion. This preliminary configuration ensures that a single infused cell population is pre-equipped with multiple antigen-specific receptors, eliminating the need for sequential infusions and simplifying the treatment protocol while maintaining specificity for each target antigen.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.